HomeAI · summaries
Storia in 2 fonti
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
Minoryx's leriglitazone (Nezglyal) won EU backing after two prior rejections, while CHMP rejected Zevra's arimoclomol (Meplyffa).
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
Minoryx's leriglitazone (Nezglyal) won EU backing after two prior rejections, while CHMP rejected Zevra's arimoclomol (Meplyffa).
- ·
benzinga.com
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C - Zevra Ther
The CHMP issues a negative opinion on Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C, prompting a re-examination request.